In Silicon Valley, a controversial trend is gaining traction, with startups offering parents the chance to influence their future child's intelligence, height, and reduce the risk of serious diseases. Nucleus, a leading California startup, launched a campaign in 2025 under the slogan "Raise Your Best Child," tapping into the burgeoning market of polygenic risk testing. This new technology, employed during in vitro fertilization (IVF), claims to provide unprecedented opportunities for prospective parents, including the potential to enhance a child's IQ or mitigate the likelihood of developing conditions such as type 2 diabetes. However, behind the bold marketing claims lie significant uncertainties and ethical dilemmas.
The American Society for Reproductive Medicine (ASRM), a prominent organization in reproductive health, publicly opposed the practice of polygenic testing in December 2025, highlighting concerns that such tests may not deliver the promised results. Critics argue that this burgeoning technology may exacerbate existing social inequalities, as the most enthusiastic proponents of these innovations tend to be affluent entrepreneurs and investors in Silicon Valley who seek to leave behind a "better version of themselves."
The distinction between traditional genetic testing and the new polygenic tests is crucial. While standard pre-implantation genetic testing (PGT) focuses on specific genetic disorders caused by single gene mutations, polygenic tests assess the risk for traits influenced by multiple genes. This may include common conditions like diabetes and schizophrenia, but the accuracy and clinical value of these tests remain unproven.
Reproductive specialists caution against the implementation of polygenic testing, citing a lack of solid evidence supporting its reliability and the ethical implications it raises. Concerns include unequal access to such technologies and the prioritization of certain health conditions over others, potentially leading to biased risk assessments.
As this trend develops, it raises critical questions about the implications for future generations and the ethical landscape of reproductive technology. The potential for enhanced genetic selection could reshape societal norms and healthcare access, making it imperative for stakeholders to approach these advancements with caution. For the market and competitors, this signifies a growing demand for innovative reproductive technologies, while also necessitating a dialogue about the ethical frameworks that should govern their use.
Informational material. 18+.
